- PR Newswire•8 days agoSynthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms
ROCKVILLE, Md., Sept. 20, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that following the completion of a previously planned interim analysis by an independent Interim Analysis Committee (IAC), enrollment has been completed in its Phase 2b randomized, placebo-controlled, proof-of-concept clinical trial for SYN-004 (ribaxamase). Following a closed session with the IAC in which the Company remained blinded to the study data, a recommendation was given to continue the study per protocol without modification and no safety issues were identified. The Company anticipates announcing top-line results during the first quarter of 2017.
- Investor's Business Daily•12 days ago
A community of drone tinkerers is creating a groundswell of activity that some have compared to the early years of the PC revolution.
- TheStreet.com•13 days ago
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Synthetic Biologics Inc. (SYN)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
|Bid||1.80 x 1700|
|Ask||1.82 x 400|
|Day's Range||1.78 - 1.89|
|52wk Range||0.93 - 3.09|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.43|
|Avg Vol (3m)||353,848|
|Dividend & Yield||N/A (N/A)|